IFNB1 and multiple sclerosis: People with multiple sclerosis treated with high-potency DMT (natalizumab) had the lowest inflammation-based protein levels when compared to people with multiple sclerosis treated with IFN-β, glatiramer acetate or not treated with any DMT.